Automated PCR Platform Increases Productivity of Clinical Molecular Diagnostic Laboratories
By LabMedica International staff writers Posted on 09 Dec 2015 |
An automated real-time PCR platform that has been certified for diagnostics use in Europe (CE-marked) has demonstrated the potential to dramatically improve productivity and turnaround times in the clinical laboratory.
The Beckman Coulter Diagnostics (Nyon, Switzerland) DxN VERIS Molecular Diagnostics System integrates sample introduction, nucleic acid extraction, reaction setup, real-time PCR amplification and detection (using Roche [Basel, Switzerland] TaqMan chemistry), and results interpretation for a fully streamlined workflow. This system offers some important workflow advantages compared to current methods for the determination of viral loads for HIV-1, HCV, HBV, and CMV. For example, the DxN VERIS system allows continuous loading of samples, which eliminates the need for batching and, with true, single sample random access, it allows urgent samples to be added at any time.
As a fully automated system, DxN VERIS decreases the potential for human error and reduces turnaround times considerably compared to the current methods, which allows much faster reporting of results to service users. Unlike current methods, technicians are not required to pipette samples and reagents, which is an important ergonomic advantage. By reducing manual time requirements it enables laboratories to achieve the most from existing staffing levels, helping to maximize productivity within the laboratory.
A case study conducted at the department of clinical microbiology of the University of Barcelona School of Medicine (Spain) demonstrated that the DxN VERIS workflow involved far fewer steps, particularly during the preanalytical stage. It also highlighted the system's reduced hands-on time and lower demand for consumables.
Dr. Jordi Vila, head of the department of clinical microbiology at the University of Barcelona School of Medicine, said, “The implementation of automated methodologies, such as the DxN VERIS, has the potential to improve the quality and delivery of virology services and, for patients, it allows infectious disease results to be obtained at the earliest opportunity with high sensitivity and specificity. In addition to this, consolidation of extraction, amplification, and detection onto a single platform is considered an important factor for laboratories, like ours, where space is very limited.”
Related Links:
Beckman Coulter Diagnostics
Roche
University of Barcelona School of Medicine
The Beckman Coulter Diagnostics (Nyon, Switzerland) DxN VERIS Molecular Diagnostics System integrates sample introduction, nucleic acid extraction, reaction setup, real-time PCR amplification and detection (using Roche [Basel, Switzerland] TaqMan chemistry), and results interpretation for a fully streamlined workflow. This system offers some important workflow advantages compared to current methods for the determination of viral loads for HIV-1, HCV, HBV, and CMV. For example, the DxN VERIS system allows continuous loading of samples, which eliminates the need for batching and, with true, single sample random access, it allows urgent samples to be added at any time.
As a fully automated system, DxN VERIS decreases the potential for human error and reduces turnaround times considerably compared to the current methods, which allows much faster reporting of results to service users. Unlike current methods, technicians are not required to pipette samples and reagents, which is an important ergonomic advantage. By reducing manual time requirements it enables laboratories to achieve the most from existing staffing levels, helping to maximize productivity within the laboratory.
A case study conducted at the department of clinical microbiology of the University of Barcelona School of Medicine (Spain) demonstrated that the DxN VERIS workflow involved far fewer steps, particularly during the preanalytical stage. It also highlighted the system's reduced hands-on time and lower demand for consumables.
Dr. Jordi Vila, head of the department of clinical microbiology at the University of Barcelona School of Medicine, said, “The implementation of automated methodologies, such as the DxN VERIS, has the potential to improve the quality and delivery of virology services and, for patients, it allows infectious disease results to be obtained at the earliest opportunity with high sensitivity and specificity. In addition to this, consolidation of extraction, amplification, and detection onto a single platform is considered an important factor for laboratories, like ours, where space is very limited.”
Related Links:
Beckman Coulter Diagnostics
Roche
University of Barcelona School of Medicine
Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!

Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Technology News
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more